Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Clinical trial NCT06093425 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06093425
- Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2029-10-01
- Enrollment
- 820
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.